Site News
Strait of Hormuz on the brink of explosion: U.S.-Iran confrontation threatens Gulf security and leaves the region facing open-ended scenariosWeather tops concerns across the Arab world: rain, floods and unstable conditions cause worry in 14 countriesBreaking: Bahrain’s Interior Ministry issues warning of danger, urges citizens and residents to remain calmAKANAN PRODUCTIONS to Host Ehab Tawfiq Concert in Lebanon on December 12, 2026England defeats Spain at home with a historic three-goal victory, ending their longest unbeaten runEbola threatens a widespread epidemic in Africa — over 11,000 cases and 5,400 deaths; clashes hamper containment efforts.Maha Shhadeh at Global Education Summit 2026: Where AI, Human Potential and Education MeetKRATOS Launches Worldwide Expansion with Premium Quality and Accessible Pricing
Economy

Trump Reaches Drug Pricing Deal With AstraZeneca

U.S. President Donald Trump participates in a bilateral meeting with Finland's President Alexander Stubb (not pictured), in the Oval office at the White House…

100%
Trump Reaches Drug Pricing Deal With AstraZeneca

U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025.

Nathan Howard | Reuters

The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday.

The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizerwhich was announced late last month.

President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC.

Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing.

It is unclear if the deal with AstraZeneca would also include such a carveout.

AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement.

Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S.

Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead.

“If we don’t make a deal, we’re going to tariff them,” he said late last month as he announced the Pfizer agreement.

This story is developing. Please check back for updates.

Disclaimer: This news article has been republished exactly as it appeared on its original source, without any modification.
We do not take any responsibility for its content, which remains solely the responsibility of the original publisher.


Disclaimer: This news article has been republished exactly as it appeared on its original source, without any modification.
We do not take any responsibility for its content, which remains solely the responsibility of the original publisher.


Author: uaetodaynews
Published on: 2025-10-10 19:34:00
Source: uaetodaynews.com

megastar-news.com — News Update